Pluss unveils Celsure XL VIP pallets
A game changing solution for the pharmaceutical industry
A game changing solution for the pharmaceutical industry
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The company plans to add 1700 beds by FY27 through the organic route
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
New leadership team announced at NATHEALTH Annual General Meeting 2024
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
Subscribe To Our Newsletter & Stay Updated